Catalyst Pharmaceuticals Stock In The News
| CPRX Stock | USD 21.44 0.29 1.37% |
Our overall analysis of Catalyst Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Catalyst Pharmaceuticals. The specific impact of Catalyst Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Catalyst Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Catalyst Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Catalyst Pharmaceuticals Backtesting and Catalyst Pharmaceuticals Hype Analysis. For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.
Catalyst |
Catalyst Pharmaceuticals Today Top News and Investor Outlook
Catalyst Pharmaceuticals Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Catalyst and other traded companies coverage with news coverage. We help investors stay connected with Catalyst headlines for the 22nd of November to make an informed investment decision based on correlating the impacts of news items on Catalyst Stock performance. Please note that trading solely based on the Catalyst Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
Catalyst Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Catalyst earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Catalyst Pharmaceuticals that are available to investors today. That information is available publicly through Catalyst media outlets and privately through word of mouth or via Catalyst internal channels. However, regardless of the origin, that massive amount of Catalyst data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Catalyst Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Catalyst Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Catalyst Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Catalyst Pharmaceuticals alpha.
Catalyst Largest EPS Surprises
Earnings surprises can significantly impact Catalyst Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-08-09 | 2021-06-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2020-11-09 | 2020-09-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2020-05-11 | 2020-03-31 | 0.09 | 0.1 | 0.01 | 11 | ||
2018-11-07 | 2018-09-30 | -0.07 | -0.08 | -0.01 | 14 | ||
2018-08-07 | 2018-06-30 | -0.07 | -0.06 | 0.01 | 14 | ||
2017-08-09 | 2017-06-30 | -0.06 | -0.05 | 0.01 | 16 |
Catalyst Pharmaceuticals Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Catalyst Pharmaceuticals Stock. Current markets are slightly bullish. About 58% of major world exchanges and indexes are currently up. See today's market update for more information.
20th of November 2024
Disposition of 72500 shares by Patrick McEnany of Catalyst Pharmaceuticals at 3.54 subject... at MacroaxisInsider
15th of November 2024
Heres Why Catalyst Pharmaceutical is a Strong Growth Stock at zacks.com
13th of November 2024
Catalyst Pharmaceuticals chairman sells 11.5 million in stock at investing.com
7th of November 2024
Earnings call Catalyst Pharma reports robust Q3 results, raises guidance at investing.com
6th of November 2024
Catalyst Reports Q3 Earnings What Key Metrics Have to Say at zacks.com
5th of November 2024
Catalyst Pharmaceuticals Q3 2024 Earnings Preview at seekingalpha.com
17th of October 2024
STATE STREET CORPs Strategic Reduction in Catalyst Pharmaceuticals Holdings at gurufocus.com
19th of September 2024
Catalyst Pharmaceuticals stock hits 52-week high at 20.88 - Investing.com at news.google.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Catalyst Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Catalyst Pharmaceuticals' short interest history, or implied volatility extrapolated from Catalyst Pharmaceuticals options trading.
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.